Cargando…
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
BACKGROUND: The clinical course of breast cancer patients with brain metastases (BM) as only metastatic site (brain-only metastatic breast cancer (BO-MBC)) has been insufficiently explored. METHODS: All breast cancer patients with BM treated at our institution between 1990 and 2011 were identified....
Autores principales: | Berghoff, A S, Bago-Horvath, Z, Ilhan-Mutlu, A, Magerle, M, Dieckmann, K, Marosi, C, Birner, P, Widhalm, G, Steger, G G, Zielinski, C C, Bartsch, R, Preusser, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493775/ https://www.ncbi.nlm.nih.gov/pubmed/23047551 http://dx.doi.org/10.1038/bjc.2012.440 |
Ejemplares similares
-
Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times
por: Berghoff, Anna Sophie, et al.
Publicado: (2013) -
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021) -
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
por: Berghoff, Anna S, et al.
Publicado: (2016) -
Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021) -
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)